One-year evaluation of paliperidone palmitate 6-monthly: satisfaction and perceived effectiveness among patients, relatives, and clinicians
File(s)
Author(s)
Manchado Perero, Sofia
Rodriguez Lorente, Ana
Garcia-Perez, Alba
Isidro García, Guillermo
Forcen-Muñoz, Luis Alberto
Type
Journal Article
Abstract
Background: Patient satisfaction and perceived treatment effectiveness play a critical role in healthcare outcomes and overall well-being. Understanding patient experiences can help identify barriers to adherence and guide improvements in therapy. Previous studies, such as those conducted with PP3M and PP1M, have highlighted the importance of patient satisfaction in optimizing the management of chronic conditions, demonstrating that satisfaction is linked to better adherence and overall treatment success. Nonetheless, there was no data available with patients treated with paliperidone 6-month (PP6M). Therefore, we aimed to evaluate the perspectives, including the perceived effectiveness and satisfaction of patients, their relatives and mental health professionals on the twice-yearly treatment with PP6M in usual clinical practice.
Methods: The cohort of patients derived from the P2Y study. This is a multicenter, prospective study across different sites in Europe. Patients, relatives and psychiatrists were asked for satisfaction, by using the Medication Satisfaction Questionnaire (MSQ), and perceived effectiveness. We included all patients who were initiated or switched to PP6M and completed one year of treatment.
Results: A total of 233 patients were included in this study, of which 9 (4%) discontinued PP6M at 12 months. Most patients were male (69%, 160 participants), 66% (156 patients) carried a diagnosis of schizophrenia and 16% (38 patients) of comorbid substance use disorder. Furthermore, 22% (51 patients), 70% (164 patients) and 8% (19 patients) were treated with PP1M, PP3M and other oral/LAIs antipsychotics, respectively. The majority of patients (81.5%, n = 190/233), relatives/carers (81.1%, n = 189/233) and clinicians (90.9%, n = 212/233) were extremely satisfied, very satisfied or satisfied 1 year after switching from PP1M, PP3M and other antipsychotic to PP6M with similar findings between patients diagnosed with schizophrenia and other diagnoses. Last, 42% of patients, 45% of their relatives and 40% of clinicians perceived PP6M as more effective compared to the previous treatment. In contrast, only 3% of patients, relatives and clinicians perceived PP6M as less effective.
Conclusion: Patients, their carers and relatives as well as mental health professionals reported a high satisfaction rate with PP6M, and equally good or even better perceived effectiveness compared to PP1M, PP3M or other oral or LAIs antipsychotics in the majority of cases. Improved patient experience with PP6M could improve treatment continuity and reduce hospitalization rates.
Methods: The cohort of patients derived from the P2Y study. This is a multicenter, prospective study across different sites in Europe. Patients, relatives and psychiatrists were asked for satisfaction, by using the Medication Satisfaction Questionnaire (MSQ), and perceived effectiveness. We included all patients who were initiated or switched to PP6M and completed one year of treatment.
Results: A total of 233 patients were included in this study, of which 9 (4%) discontinued PP6M at 12 months. Most patients were male (69%, 160 participants), 66% (156 patients) carried a diagnosis of schizophrenia and 16% (38 patients) of comorbid substance use disorder. Furthermore, 22% (51 patients), 70% (164 patients) and 8% (19 patients) were treated with PP1M, PP3M and other oral/LAIs antipsychotics, respectively. The majority of patients (81.5%, n = 190/233), relatives/carers (81.1%, n = 189/233) and clinicians (90.9%, n = 212/233) were extremely satisfied, very satisfied or satisfied 1 year after switching from PP1M, PP3M and other antipsychotic to PP6M with similar findings between patients diagnosed with schizophrenia and other diagnoses. Last, 42% of patients, 45% of their relatives and 40% of clinicians perceived PP6M as more effective compared to the previous treatment. In contrast, only 3% of patients, relatives and clinicians perceived PP6M as less effective.
Conclusion: Patients, their carers and relatives as well as mental health professionals reported a high satisfaction rate with PP6M, and equally good or even better perceived effectiveness compared to PP1M, PP3M or other oral or LAIs antipsychotics in the majority of cases. Improved patient experience with PP6M could improve treatment continuity and reduce hospitalization rates.
Date Issued
2025-05-28
Date Acceptance
2025-04-22
Citation
Patient Preference and Adherence, 2025, 19, pp.1573-1582
ISSN
1177-889X
Publisher
Dove Medical Press
Start Page
1573
End Page
1582
Journal / Book Title
Patient Preference and Adherence
Volume
19
Copyright Statement
© 2025 Manchado Perero et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress. com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v4.0) License (http://creativecommons.org/licenses/by-nc/4.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php)
License URL
Identifier
10.2147/PPA.S517038
Subjects
paliperidone-palmitate 6-monthly
schizophrenia
long-acting injectable antipsychotics
patient satisfaction
psychiatrists and family perspectives
effectiveness
Publication Status
Published